NCT06684197 The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption
| NCT ID | NCT06684197 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ciusss de L'Est de l'Île de Montréal |
| Condition | Dexmedetomidine |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2025-05-09 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72 participants in total. It began in 2025-05-09 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Opioids analgesic are the gold standard for intraoperative pain management. Their short- and long-term adverse effect motivate anesthesiologists to explore opioid sparing strategies. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that could help minimize opioid consumption both intraoperative and postoperative due to its sedative, analgesic and sympatholytic properties. This new randomized controlled trial (RCT) will answer the question whether an intraoperative dexmedetomidine infusion compared to placebo has a clinically significant impact on intraoperative remifentanil consumption during a laparoscopic abdominal elective surgery.
Eligibility Criteria
Inclusion Criteria: * ASA 1-3 * Laparascopic surgery (including general surgery, gynecology, urology) a small abdominal incision (less than 5 cm) will be tolerated. Exclusion Criteria: * Patient refusal * Chronic use of opioids * Allergy to medication used in the trial * Pregnant or breastfeeding women * Contraindications to dexmedetomidine (Bradycardia, arrythmia or pace- maker, severe ventricular dysfunction)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06684197 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Dexmedetomidine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06684197 currently recruiting?
Yes, NCT06684197 is actively recruiting participants. Contact the research team at overdonck@gmail.com for enrollment information.
Where is the NCT06684197 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT06684197 clinical trial?
NCT06684197 is sponsored by Ciusss de L'Est de l'Île de Montréal. The trial plans to enroll 72 participants.